When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
PRNB - dosing underway for Principia's rilzabrutinib mid-stage study in IgG4-related disease
Principia Biopharma Inc.
Principia Biopharma (NASDAQ:PRNB) has dosed the first patient in an open label two-arm Phase 2A trial, evaluating rilzabrutinib in IgG4-related disease (RD), an immune-mediated fibroinflammatory condition that is capable of affecting multiple organs.
More news on: Principia Biopharma Inc., Healthcare stocks news,